Biohit OyjLTS:0DRP +3.79%78 PB Ratio is 2.79 as of Jul. 05, 2026, which is 21% below its 10-year median of 3.53. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.79 (Fairly Valued). The stock has 3 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 59.77% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Biohit Oyj's share price is €2.74. Biohit Oyj's Book Value per Share for the quarter that ended in Dec. 2025 was €0.98. Hence, Biohit Oyj's PB Ratio of today is 2.79.
The historical rank and industry rank for Biohit Oyj's PB Ratio or its related term are showing as below:
LTS:0DRP'
s PB Ratio Range Over the Past 10 Years
Min: 2.02 Med: 3.53 Max: 8.77
Current: 2.77
During the past 13 years, Biohit Oyj's highest PB Ratio was 8.77. The lowest was 2.02. And the median was 3.53.
LTS:0DRP's PB Ratio is ranked worse than 59.77% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs LTS:0DRP: 2.77
During the past 12 months, Biohit Oyj's average Book Value Per Share Growth Rate was 22.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biohit Oyj was 59.00% per year. The lowest was -38.60% per year. And the median was 2.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Biohit Oyj PB Ratio Related Terms
Biohit Oyj PB Ratio Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Biohit Oyj's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Biohit Oyj (LTS:0DRP) has a PB Ratio of 2.79 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biohit Oyj and its competitors. This is 21% below median its historical median of 3.53. Over the past decade, Biohit Oyj's PB Ratio has ranged from 2.02 to 8.77. According to the industry distribution chart, Biohit Oyj ranks #471 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 59.8%.
Is Biohit Oyj's PB Ratio too high?
Biohit Oyj's current PB Ratio of 2.79 is 21% below median its 10-year median of 3.53. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 8.77. The Medical Devices & Instruments industry median PB Ratio is 2.07. Biohit Oyj's value of 2.79 is 34.8% above this industry median. Based on the distribution chart, Biohit Oyj ranks #471 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #471 out of 788 companies for PB Ratio. This places Biohit Oyj in the lower half of its industry. The industry median PB Ratio is 2.07. Biohit Oyj's value of 2.79 is 34.8% above this benchmark. Historically, Biohit Oyj's own PB Ratio has ranged from 2.02 to 8.77 over the past decade. While the company's 10-year median is 3.53 vs. the industry median of 2.07, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.07, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current PB Ratio of 2.79 is 34.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current PB Ratio is 2.79, which is 21% below median its own 10-year median of 3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.79, compared to a current price of €2.74 — trading 1.8% below its estimated fair value. The current PB Ratio is 2.79, which is 21% below median its 10-year median of 3.53 and 34.8% above the Medical Devices & Instruments industry median of 2.07. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current PB Ratio is 2.79 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.74 is trading 1.8% below its estimated GF Value™ of €2.79.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
PB Ratio: 2.79 (21% below median its 10-year median of 3.53)
GF Value™: €2.79 vs. price of €2.74 (1.8% below fair value)
Industry Position: 34.8% above the Medical Devices & Instruments median (#471 of 788)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
